For people with HIV and fatty liver disease on certain HIV drugs, taking tesamorelin for a year likely reduces belly fat by 8.3% while placebo makes it increase by 10.8%.

Scientific Claim

In people with HIV and non-alcoholic fatty liver disease receiving integrase inhibitor therapy, tesamorelin treatment for 12 months is likely associated with an 8.3% reduction in visceral adipose tissue compared to a 10.8% increase in the placebo group (p=0.0034).

Original Statement

“After 12 months, there was a significant difference in VAT change between the placebo and tesamorelin treated groups (p=0.0034). The placebo group had an increase in VAT of 10.8% whereas the Tesamorelin treated group had an overall reduction in VAT of 8.3%.”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

probability

Can suggest probability/likelihood

Assessment Explanation

The study is an RCT with randomization and control group, allowing causal inference, but blinding status unknown introduces some bias. Using 'likely associated' appropriately reflects the probabilistic nature of the finding given the limitations.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

For people with HIV and fatty liver disease who are taking integrase inhibitor drugs, taking tesamorelin for a year likely helped reduce belly fat, while those on a placebo saw their belly fat increase.

99%

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

96%

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

95%

For people with HIV and fatty liver disease on INSTI drugs, tesamorelin likely reduces liver fat by 4.9% while placebo has almost no effect (0.1% decrease) after a year.

95%

For people with HIV and fatty liver who are on INSTI drugs, taking tesamorelin for a year likely reduces belly fat by 8.3%, while those on a placebo see a 10.8% increase in belly fat.

94%